These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2316207)
1. Development of an immunoaffinity process for factor IX purification. Tharakan J; Strickland D; Burgess W; Drohan WN; Clark DB Vox Sang; 1990; 58(1):21-9. PubMed ID: 2316207 [TBL] [Abstract][Full Text] [Related]
2. Immunopurification of human coagulation factor IX using monoclonal antibodies. Bessos H; Prowse CV Thromb Haemost; 1986 Aug; 56(1):86-9. PubMed ID: 3775693 [TBL] [Abstract][Full Text] [Related]
3. Effect of feed flow-rate, antigen concentration and antibody density on immunoaffinity purification of coagulation factor IX. Tharakan JP; Clark DB; Drohan WN J Chromatogr; 1990 Nov; 522():153-62. PubMed ID: 2081750 [TBL] [Abstract][Full Text] [Related]
4. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex. Liebman HA; Limentani SA; Furie BC; Furie B Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX. Highsmith F; Regan T; Clark D; Drohan W; Tharakan J Biotechniques; 1992 Mar; 12(3):418-23. PubMed ID: 1571154 [TBL] [Abstract][Full Text] [Related]
6. Rapid purification of factor IX, factor X and prothrombin by immunoaffinity and ion exchange chromatography. Ahmad SS; Rawala-Sheikh R; Thompson AR; Walsh PN Thromb Res; 1989 Jul; 55(1):121-33. PubMed ID: 2781515 [TBL] [Abstract][Full Text] [Related]
7. Purification and characterization of rabbit factor IX and its existence as a two-chain factor IX alpha in circulating plasma. Rao LV; Hoang AD Thromb Res; 1991 Oct; 64(1):57-68. PubMed ID: 1776139 [TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity purification of protein C by using conformation-specific monoclonal antibodies to protein C-calcium ion complex. Nakamura S; Sakata Y Biochim Biophys Acta; 1987 Aug; 925(2):85-93. PubMed ID: 3620498 [TBL] [Abstract][Full Text] [Related]
9. Physical and biochemical characterization of five commercial resins for immunoaffinity purification of factor IX. Tharakan J; Highsmith F; Clark D; Drohan W J Chromatogr; 1992 Mar; 595(1-2):103-11. PubMed ID: 1577903 [TBL] [Abstract][Full Text] [Related]
10. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody. Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674 [TBL] [Abstract][Full Text] [Related]
11. Separation of human plasma factor IX from HTLV-I or HIV by immunoaffinity chromatography using conformation-specific antibodies. Limentani SA; Furie BC; Poiesz BJ; Montagna R; Wells K; Furie B Blood; 1987 Nov; 70(5):1312-5. PubMed ID: 2822170 [TBL] [Abstract][Full Text] [Related]
12. Homologous human blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of factor IX and prothrombin. Wu H; Bruley DF Biotechnol Prog; 1999; 15(5):928-31. PubMed ID: 10514264 [TBL] [Abstract][Full Text] [Related]
13. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. Berndt MC; Gregory C; Kabral A; Zola H; Fournier D; Castaldi PA Eur J Biochem; 1985 Sep; 151(3):637-49. PubMed ID: 3161731 [TBL] [Abstract][Full Text] [Related]
14. Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns. Jenny R; Church W; Odegaard B; Litwiller R; Mann K Prep Biochem; 1986; 16(3):227-45. PubMed ID: 3748998 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322 [TBL] [Abstract][Full Text] [Related]
16. Use of proteomics for validation of the isolation process of clotting factor IX from human plasma. Clifton J; Huang F; Gaso-Sokac D; Brilliant K; Hixson D; Josic D J Proteomics; 2010 Jan; 73(3):678-88. PubMed ID: 19819359 [TBL] [Abstract][Full Text] [Related]
17. Inactivation and clearance of viruses during the manufacture of high purity factor IX. Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439 [TBL] [Abstract][Full Text] [Related]
18. Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports. Ribeiro DA; Passos DF; Ferraz HC; Castilho LR J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 938():111-8. PubMed ID: 24076525 [TBL] [Abstract][Full Text] [Related]
19. Preparation and properties of a therapeutic factor IX concentrate. Suomela H; Myllylä G; Raaska E Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244 [TBL] [Abstract][Full Text] [Related]
20. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5. Chang YJ; Wu HL; Hsu YC; Hamaguchi N; Shi GY; Shen MC; Lin SW Thromb Res; 2003; 111(4-5):293-9. PubMed ID: 14693178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]